Dynamic changes in peripheral blood lymphocyte subsets predict the efficacy and prognosis of immune checkpoint inhibitors in metastatic osteosarcoma - Summary - MDSpire
Advertisement
Dynamic changes in peripheral blood lymphocyte subsets predict the efficacy and prognosis of immune checkpoint inhibitors in metastatic osteosarcoma
To examine fluctuations in peripheral blood lymphocyte subsets in metastatic osteosarcoma patients undergoing immune checkpoint inhibitor therapy, emphasizing the significance of identifying potential biomarkers for treatment response and prognosis.
Key Findings:
Pre-ICIs CD8+HLA-DR+ cells and post-ICIs CD3−CD56+, CD3+CD4+, and CD8+HLA-DR+ cells were indicators associated with improved overall survival.
Patients achieving disease control had significantly higher counts of CD45+, CD3−CD56+, CD4+HLA-DR+, CD3+CD8+, and CD8+HLA-DR+ at diagnosis.
Dynamic increases in post-ICIs CD3−CD56+ and CD8+HLA-DR+ cells correlated with improved treatment response.
Extrapulmonary metastasis was identified as a significant risk factor for unfavorable overall survival.
Interpretation:
Increased levels and dynamic changes in specific peripheral blood lymphocyte subsets post-ICIs are associated with better overall survival and treatment response in metastatic osteosarcoma patients, with implications for clinical practice.
Limitations:
Small sample size of 14 patients limits generalizability.
Retrospective design may introduce bias affecting data reliability.
Conclusion:
This study highlights the potential of peripheral blood lymphocyte subsets as non-invasive biomarkers for predicting ICI efficacy and guiding personalized treatment in metastatic osteosarcoma, warranting further validation in larger cohorts to confirm these findings.
